Related Experiment Video
Updated: Aug 16, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 as early predictors of growth, body
Megan E Paulsen1,2,3, Nicholas Marka4, Scott Lunos4
1Division of Neonatology, Department of Pediatrics, University of Minnesota Medical School, Minneapolis, MN, USA. megan.paulsen@childrensmn.org.
Insights
Early insulin-like growth factor binding protein 3 (IGFBP-3) levels in preterm infants correlate with better neurodevelopment. Insulin-like growth factor 1 (IGF-1) is linked to improved growth outcomes.
Area of Science:
- Neonatal Research
- Endocrinology
- Developmental Pediatrics
Background:
- Preterm infants face risks for impaired growth, body composition, and neurodevelopment.
- Insulin-like growth factor 1 (IGF-1) and IGF binding protein 3 (IGFBP-3) are crucial for fetal and postnatal development.
- Understanding their role in preterm infants is vital for optimizing long-term outcomes.
Purpose of the Study:
- To examine the association between IGF-1, IGFBP-3 levels and growth, body composition, and neurodevelopment in preterm infants.
- To identify potential early biomarkers for predicting long-term outcomes in this vulnerable population.
Main Methods:
- Prospective cohort study of 50 infants born at or before 32 weeks gestational age.
- Measurement of IGF-1 and IGFBP-3 at 1 week (early) and 35 weeks (late) post-menstrual age (PMA).
- Assessment of growth, body composition, and neurodevelopment at 4 and 12 months PMA using linear regression analysis.
Main Results:
- Early IGFBP-3 concentrations positively correlated with neurodevelopment at 12 months PMA.
- Early IGF-1 concentrations were associated with increased weight at 4 months PMA, head circumference at 12 months PMA, and body mass index at 12 months PMA.
- Late IGFBP-3 concentrations showed a positive association with weight at 4 months PMA.
Conclusions:
- Early IGF-1 and IGFBP-3 levels may serve as predictive biomarkers for growth and neurodevelopmental outcomes in preterm infants.
- These findings suggest potential targets for therapeutic interventions to improve health in preterm populations.
- Further research is warranted to explore these associations for novel biomarker and treatment development.
Objective:
To investigate the relationship between insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3) and long-term growth, body composition, and neurodevelopment in preterm infants.
Study Design:
Prospective data were collected from ≤32 weeks gestational age infant cohort (N = 50). IGF-1 and IGFBP-3 concentrations were measured at 1 week (early) and 35 weeks (late) post-menstrual age (PMA). Growth, body composition, and neurodevelopment outcomes were measured at 4 and 12 months PMA. Relationships were measured by linear regression analysis.
Results:
Early IGFBP-3 concentration was positively associated with neurodevelopment at 12 months PMA. Early IGF-1 concentration was positively associated with weight at 4 months PMA, head circumference at 12 months PMA, and body mass index at 12 months PMA. Late IGFBP-3 concentration was positively associated with weight at 4 months PMA.
Conclusion:
Further investigation of these associations may lead to novel biomarkers and/or treatments to optimize health outcomes in preterm infants.
Related Concept Videos
Nature and Nurture
Determination
Mitogens and the Cell Cycle
Environmental Influences on Intelligence

